David F. Carroll
Net Worth

Last updated:

What is David F. Carroll net worth?

The estimated net worth of Mr. David F. Carroll is at least $12,095,062 as of 1 May 2023. He has earned $7,026,422 from insider trading and has received compensation worth at least $5,068,640 in IVERIC bio, Inc..

What is the salary of David F. Carroll?

Mr. David F. Carroll salary is $633,580 per year as Senior Vice President, Chief Financial Officer & Treasurer in IVERIC bio, Inc..

How old is David F. Carroll?

Mr. David F. Carroll is 59 years old, born in 1966.

What stocks does David F. Carroll currently own?

As insider, Mr. David F. Carroll owns shares in one company:

Company Title Shares Price per share Total value
IVERIC bio, Inc. (ISEE) Senior Vice President, Chief Financial Officer & Treasurer 68,472 $0 $0

What does IVERIC bio, Inc. do?

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

ISEE logo
ISEE
IVERIC bio, Inc.

David F. Carroll insider trading

IVERIC bio, Inc.

Mr. David F. Carroll has made 23 insider trades between 2017-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 63,500 units of ISEE stock on 1 May 2023. As of 1 May 2023 he still owns at least 68,472 units of ISEE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 63,500 $2.81 $178,435
Option
Stock Option (right to buy) 63,500 $2.81 $178,435
Sale
Common Stock 63,500 $37.04 $2,352,040
Sale
Common Stock 48,171 $30.21 $1,455,246
Option
Common Stock 48,171 $1.45 $69,848
Option
Stock Option (right to buy) 48,171 $1.45 $69,848
Option
Stock Option (right to buy) 1,829 $1.45 $2,652
Option
Common Stock 1,829 $1.45 $2,652
Sale
Common Stock 1,829 $30 $54,870
Sale
Common Stock 3,602 $20.06 $72,256
Option
Restricted Stock Units 8,750 N/A N/A
Option
Common Stock 8,750 N/A N/A
Sale
Common Stock 5,671 $21.51 $121,983
Option
Restricted Stock Units 14,375 N/A N/A
Option
Common Stock 14,375 N/A N/A
Sale
Common Stock 4,932 $21.73 $107,172
Sale
Common Stock 2,405 $20.66 $49,687
Option
Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Sale
Common Stock 1,541 $21.25 $32,746
Option
Common Stock 10,000 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Sale
Common Stock 4,684 $19.01 $89,043
Option
Common Stock 4,684 $1.45 $6,792
Option
Stock Option (right to buy) 4,684 $1.45 $6,792
Option
Stock Option (right to buy) 20,316 $1.45 $29,458
Sale
Common Stock 600 $19.01 $11,406
Sale
Common Stock 40,341 $18.49 $745,905
Option
Common Stock 20,316 $1.45 $29,458
Sale
Common Stock 2,144 $17 $36,448
Option
Stock Option (right to buy) 16,763 $1.45 $24,306
Sale
Common Stock 16,772 $17.02 $285,392
Option
Common Stock 16,763 $1.45 $24,306
Sale
Common Stock 11,561 $17 $196,560
Option
Common Stock 8,237 $1.45 $11,944
Option
Stock Option (right to buy) 8,237 $1.45 $11,944
Sale
Common Stock 15,819 $16.39 $259,305
Option
Restricted Stock Units 32,500 N/A N/A
Option
Common Stock 32,500 N/A N/A
Sale
Common Stock 56,207 $15.98 $898,356
Sale
Common Stock 6,710 $15.44 $103,629
Option
Restricted Stock Units 14,375 N/A N/A
Option
Common Stock 14,375 N/A N/A
Sale
Common Stock 5,836 $14.75 $86,052
Option
Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Sale
Common Stock 3,614 $14.53 $52,519
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 11,875 N/A N/A
Option
Common Stock 32,500 N/A N/A
Option
Restricted Stock Units 32,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Restricted Stock Units 12,500 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Sale
Common Stock 2,773 N/A N/A
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Sale
Common Stock 2,736 $2.68 $7,332
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Sale
Common Stock 3,284 $2.58 $8,473
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A

IVERIC bio key executives

IVERIC bio, Inc. executives and other stock owners filed with the SEC:

  • Dr. Pravin U. Dugel M.D. (61) Pres
  • Mr. David F. Carroll (59) Senior Vice President, Chief Financial Officer & Treasurer
  • Mr. Glenn P. Sblendorio M.B.A. (69) Chief Executive Officer & Director
  • Mr. Keith Westby M.B.A. (50) Senior Vice President & Chief Operating Officer